Document is current

Article History

Received: 23 July 2020

Revised: 16 March 2021

Accepted: 17 March 2021

First Online: 15 April 2021

Declaration

:

: Morio Matsumoto: personal fees from Celgene Co., Ltd, Janssen Pharmaceuticals, Bristol Myers Squibb, K.K., Pharmaceutical Co., Ltd. Kenshi Suzuki: honoraria from Celgene, Takeda, Ono Pharmaceuticals, Amgen, Novartis, Sanofi, Bristol Myers Squibb, AbbVie, Janssen; consultancy from Amgen, Janssen, Takeda, Celgene; research funding from Bristol Myers Squibb, Celgene, Amgen. Junya Kuroda: grant (submitted work): Merck; grant (outside submitted work): Astellas Pharm Inc., Kyowa Kirin, Chugai Pharmaceuticals, Japan Blood Products Association, Daiichi Sankyo Company, Limited, Pfizer, Mochida Pharmaceutical Co., Ltd, Celgene Corporation, Ono Pharmaceuticals Co., Ltd, Sanofi, Eisai Co., Ltd, Taiho Pharmaceutical Co., Ltd, Sumitomo Dainippon Pharma Co., Ltd, Asahi Kasei Pharma Co,. Ltd, Otsuka Pharmaceutical Co., Ltd, MSD K. K., Takeda Pharmaceutical Company Limited, Shionogi Pharma Co., Ltd, Nihon Pharmaceutical Co., Ltd., Fujimoto Pharmaceutical Corporation, Nippon Shinyaku Co., Ltd, Sysmex Corporation; personal fee (outside submitted work): Astellas Pharm Inc., Kyowa Kirin, Chugai Pharmaceuticals, Japan Blood Products Association, Daiichi Sankyo Company, Ltd., Mochida Pharmaceutical Co., Ltd., Celgene Corporation, Ono Pharmaceuticals Co., Ltd., Sanofi, Eisai Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Asahi Kasei Pharma Co,. Ltd., Otsuka Pharmaceutical Co., Ltd., MSD K. K., Takeda Pharmaceutical Company, Ltd., Fujimoto Pharmaceutical Corporation, Nippon Shinyaku Co., Ltd., Sysmex Corporation, Janssen Pharmaceutical, K.K., AbbVie GK. Masafumi Taniwaki: no conflicts to disclose. Kazutaka Sunami: research funding from MSD K.K. during the conduct of the study and research funding from Astellas, Amgen, Novartis, GlaxoSmithKline, Janssen Pharmaceutical, AbbVie, Takeda Pharmaceutical, Sanofi, Bristol Myers Squibb, Ono Pharmaceutical Alexion Pharmaceutical, Daiichi Sankyo, and Celgene; honoraria from Takeda Pharmaceutical, Bristol Myers Squibb, Ono Pharmaceutical, Celgene. Hiroshi Kosugi: Honoraria: Chugai Pharmaceutical, Celgene K. K., Novartis Pharmaceuticals, Bioverative Japan, Merck, Takeda, Janssen, Japan Blood Products Organization, Bristol Myers Squibb, Ono Pharmaceutical. Kiyoshi Ando: research funding from Kyowa Kirin, Co., Ltd, Chugai Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Meiji Seika Pharma Co., Ltd. Dai Maruyama: research funding from Ono Pharmaceutical, Celgene, Takeda Pharmaceutical, Janssen Pharmaceutical, Chugai Pharmaceutical, Bristol Myers Squibb, Merck, Amgen Astellas Biopharma, Astellas Pharma, Sanofi, Novartis Pharmaceuticals, Otsuka Pharmaceutical; personal fees from Eisai, Kyowa Hakko Kirin, Zenyaku Kogyo Synmosa Biopharma, Nippon Shinyaku. Kensei Tobinai: grants from Eisai, Takeda, Mundipharma, Kyowa Kirin, Celgene, Chugai Pharmaceuticals, Ono Pharmaceuticals, Janssen, AbbVie; personal fees from Zenyaku Kogyo, Eisai, Takeda, Mundipharma, HUYA Bioscience International, Kyowa Kirin, Celgene, Chugai Pharmaceuticals, Ono Pharmaceuticals, Yakult, Daiichi Sankyo, Bristol Myers Squibb, Meiji Seika Kaisha, Solasis Pharmaceuticals, Verastem. Uma Kher: employee of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Mohammed Farooqui: employee of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, and a stockholder of Merck & Co., Inc., Kenilworth, NJ, USA. Jason Liao: employee of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Patricia Marinello: employee of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, and a stockholder of Merck & Co., Inc.; travel expenses from Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Kenji Matsuda: employee of MSD K.K., Tokyo, Japan, and a stockholder of Merck & Co., Inc., Kenilworth, NJ, USA. Yasuhiro Koh: employee of MSD K.K., Tokyo, Japan. Takashi Shimamoto: employee of MSD K.K., Tokyo, Japan, and a stockholder of Merck & Co., Inc., Kenilworth, NJ, USA. Shinsuke Iida: grant from Merck (submitted work); grants (outside of submitted work) Celgene, Janssen, Ono Pharmaceuticals, Takeda, Bristol Myers Squibb, Novartis, Daiichi Sankyo, Chugai, Kyowa Kirin, AbbVie, Gilead, Sanofi; personal fees from Celgene, Janssen, Ono Pharmaceuticals, Takeda, Bristol Myers Squibb, Novartis, Daiichi Sankyo.